Squarepoint’s Revolution Medicines RVMD Stock Holding History

Squarepoint’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.7M	Buy	120,769 +97,134	+411%	+$9.81M	0.01%	988
2025 Q4	$1.88M	Buy	23,635 +13,256	+128%	+$869K	﹤0.01%	2108
2025 Q3	$485K	Sell	10,379 -328,374	-97%	-$12.9M	﹤0.01%	3259
2025 Q2	$12.5M	Buy	338,753 +245,934	+265%	+$9.45M	0.01%	962
2025 Q1	$3.28M	Buy	+92,819	New	+$3.77M	﹤0.01%	1715
2023 Q4	–	Sell	-117,302	Closed	-$3.25M	–	4424
2023 Q3	$3.25M	Buy	117,302 +90,623	+340%	+$2.69M	0.01%	1462
2023 Q2	$714K	Buy	+26,679	New	+$655K	﹤0.01%	2409
2023 Q1	–	Sell	-19,271	Closed	-$459K	–	3742
2022 Q4	$459K	Buy	+19,271	New	+$410K	﹤0.01%	2331
2021 Q3	–	Sell	-145,886	Closed	-$4.63M	–	3360
2021 Q2	$4.63M	Buy	+145,886	New	+$5.09M	0.02%	759
2021 Q1	–	Sell	-14,094	Closed	-$558K	–	3543
2020 Q4	$558K	Buy	+14,094	New	+$557K	﹤0.01%	1737

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Squarepoint's RVMD Position: Q1 2026 in Review

Squarepoint increased its Revolution Medicines (RVMD) stake by 411% in Q1 2026, buying an estimated $9.81M and bringing the position to 120,769 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #988.

Squarepoint first reported a position in RVMD in Q4 2020 and has held it in 10 quarters since. The position peaked at $12.5M in Q2 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

Squarepoint held 120,769 shares of Revolution Medicines worth $11.7M as of Q1 2026.
Squarepoint bought 97,134 Revolution Medicines shares in Q1 2026, an estimated $9.81M.
Revolution Medicines made up 0.01% of Squarepoint's portfolio in Q1 2026, its #988 holding.
Squarepoint first reported a position in Revolution Medicines in Q4 2020 and has held it in 10 quarters since.
Squarepoint's Revolution Medicines position peaked at $12.5M in Q2 2025.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.